Publications

PETRA

2026

• Nijman A.D.M., Wiegers S.E., Zwezerijnen G.J.C, Verweij L, Bes A.L, Hüttmann A., Dührsen U., Kurch L., Kersten M.J., Heymans M.W., Zijlstra J.M., Boellaard R. (2026).Segmentation method comparison for baseline [18F]FDG PET-CT in follicular lymphoma patients. European journal of nuclear medicine and molecular imaging, 10.1186/s40658-026/00842-y.

2025

• Gerards, N. R., Wiegers, S. E., Bes, A. L., Eertink, J. J., Lugtenburg, P. J., Zijlstra, J. M., Boellaard, R., & Zwezerijnen, G. J. C. (2025). Can we obtain prognostic information from healthy tissue uptake and volume in baseline 18F-FDG PET/CT imaging in diffuse large B-cell lymphoma?.European journal of nuclear medicine and molecular imaging, 10.1007/s00259-025-07503-9.

• Eertink, J. J., Heymans, M. W., Wiegers, S. E., Bes, A. L., Duhrsen, U., Huttmann, A., Kurch, L., Barrington, S. F., Mikhaeel, G. N., Lugtenburg, P. J., Ceriani, L., Zucca, E., Gyorke, T., Czibor, S., Zwezerijnen, G. J. C., Boellaard, R., Zijlstra, J. M., & Hanoun, C. (2025). Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response. Haematologica, 10.3324/haematol.2024.287241.

2024

• Maria C. Ferrández, Sandeep S.V. Golla, Jakoba J. Eertink, Sanne E. Wiegers, Gerben J.C. Zwezerijnen, Martijn W. Heymans, Pieternella J. Lugtenburg, Lars Kurch, Andreas Huttmann, Christine Hanoun, Ulrich Dührsen, Sally F. Barrington, N. George Mikhaeel, Luca Ceriani Emanuele Zucca, Sándor Czibor, Tamás Györke, Martine E.D. Chamuleau, Josée M. Zijlstra, and Ronald Boellaard, on behalf of the PETRA Consortium. Validation of an Artificial Intelligence–Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma. JNM Nov24, 65(11) 1802-1807.

• Ferrández, M.C., Golla, S.S.V., Eertink, J.J. de Vries B. M., Wiegers S. E., Zwezerijnen G. J. C., Pieplenbosch S., Schilder L., Heymans M. W., Zijlstra J. M., Boellaard R. Sensitivity of an AI method for [18F]FDG PET/CT outcome prediction of diffuse large B-cell lymphoma patients to image reconstruction protocols.EJNMMI Res13, 88 (2023). 

2023

• Ferrández, M.C., Golla, S.S.V., Eertink, J.J. de Vries B. M., Lugtenburg P. J., Wiegers S.E., Zwerzerijnen G. J. C., Pieplenbosch S., Kurch L., Huttmann A., Hanoun C., Duhrsen U., de Vet H. C. W. Zijlstra J., Boellaard R. An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients. Sci Rep13, 13111 (2023).

• Eertink, J. J., Zwezerijnen, G. J. C., Heymans, M. W., Pieplenbosch, S., Wiegers, S. E., Dührsen, U., Hüttmann, A., Kurch, L., Hanoun, C., Lugtenburg, P. J., Barrington, S. F., Mikhaeel, N. G., Ceriani, L., Zucca, E., Czibor, S., Györke, T., Chamuleau, M. E. D., Hoekstra, O. S., de Vet, H. C. W., Boellaard, R., Zijlstra, J. M. (2023). Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood, 141(25), 3055–3064. 

• Zwezerijnen, G.J.C., Eertink, J.J., Ferrández, M.C.  Sanne E. Wiegers, Coreline N. Burggraaff, Pieternella J. Lugtenburg, Martijn W. Heymans, Henrica C. W. de Vet, Josée M. Zijlstra, Ronald Boellaard. Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor. Eur J Nucl Med Mol Imaging50, 486–493 (2023).

• Eertink JJ, Zwezerijnen GJC, Wiegers SE, et al. (2023). Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma. Blood Adv. 2023;7(2):214-223.

2022

• Ferrández, M.C., Eertink, J.J., Golla, S.S.V. Wiegers S. E., Zwezerijnen G. J. C., Pieplenbosch S., Zijlstra J. M., Boellaard R.Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods. EJNMMI Res12, 44 (2022). Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods - PubMed

• Eertink JJ, Zwezerijnen GJC, Cysouw MCF, et al. (2022). Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features. Eur J Nucl Med Mol Imaging. 2022;49(13):4642-4651. Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features - PubMed

• Eertink JJ, Heymans MW, Zwezerijnen GJC, et al. (2022). External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients. EJNMMI Res. 2022;12(1):58. External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients | EJNMMI Research | Full Text

• Mikhaeel, N. G., Heymans, M. W., Eertink, J. J., de Vet, H., Boellaard, R., Dührsen, U., Ceriani, L., Schmitz, C., Wiegers, S. E., Hüttmann, A., Lugtenburg, P. J., Zucca, E., Zwezerijnen, G., Hoekstra, O. S., Zijlstra, J. M., & Barrington, S. F. (2022). Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, JCO2102063. Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index | Journal of Clinical Oncology

• Eertink, J.J., van de Brug, T., Wiegers, S.E. et al. (2022). 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging 49, 932–942. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma | European Journal of Nuclear Medicine and Molecular Imaging

2021

• Barrington, S. F., Eertink, J. J., de Vet, H., George Mikhaeel, N., Hoekstra, O. S., & Zijlstra, J. M. (2021). Not Yet Time to Abandon the Deauville Criteria in Diffuse Large B-Cell Lymphoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(11), 1655–1656. Not Yet Time to Abandon the Deauville Criteria in Diffuse Large B-Cell Lymphoma | Journal of Nuclear Medicine

• Eertink JJ, Burggraaff CN, Heymans MW, et al. (2021). Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Adv. 2021;5:2375-2384. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients - PubMed

• Zwezerijnen GJ, Eertink JJ, Burggraaff CN, et al. (2021). Interobserver agreement in automated metabolic tumor volume measurements of Deauville score 4 and 5 lesions at interim (18)F-FDG PET in DLBCL. J Nucl Med. 2021. Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma | Journal of Nuclear Medicine

• Barrington SF, Zwezerijnen B, de Vet HCW, et al. (2021). Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. J Nucl Med. 2021;62:332-337 Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium | Journal of Nuclear Medicine

2020

• Burggraaff CN, Rahman F, Kassner I, et al. (2020) Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma. Mol Imaging Biol. 2020;22:1102-1110. Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma | Molecular Imaging and Biology

2019

• Burggraaff CN, de Jong A, Hoekstra OS, et al. (2019). Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46:65-79. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis | European Journal of Nuclear Medicine and Molecular Imaging

2018

• Burggraaff CN, Cornelisse AC, Hoekstra OS, et al. (2018). Interobserver Agreement of Interim and End-of-Treatment (18)F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. J Nucl Med. 2018;59:1831-1836. Interobserver Agreement of Interim and End-of-Treatment 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials | Journal of Nuclear Medicine

Consortium Members

• Dührsen U, Bockisch A, Hertenstein B, Karsten IE, Kroschinsky F, Heuser M, Hochhaus A, Höffkes H-G, Behringer D, Prange-Krex G, Tometten M, Grieshammer M, Grigoleit GU, Schmalz O, Jordan K, Bernhard H, Gaska T, Giagounidis A, Schroers R, Martens UM, Held G, Klapper W, Jöckel K-H, Nonnemacher M, Hüttmann A, on behalf of the PETAL Trial Investigators: Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial. Blood Neoplasia 1(3): 100018, 2024.

• Johansson P, Alig S, Richter J, Hanoun C, Rekowski J, Dürig J, Ylstra B, de Jong D, Klapper W, Alizadeh AA, Dührsen U, Hüttmann A. (2023). Outcome prediction by interim positron emission tomography and LgM monoclonal gammopathy in diffuse large B-cell lymphoma. Ann. Hematol. 102:3445-3455.

• Genta, S., Ghilardi, G., Cascione, L., Juskevicius, D., Tzankov, A., Schär, S., Milan, L., Pirosa, M. C., Esposito, F., Ruberto, T., Giovanella, L., Hayoz, S., Mamot, C., Dirnhofer, S., Zucca, E., & Ceriani, L. (2022). Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. Cancers, 14(4), 1018. Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study

• Ceriani, L., Milan, L., Cascione, L., Gritti, G., Dalmasso, F., Esposito, F., Pirosa, M. C., Schär, S., Bruno, A., Dirnhofer, S., Giovanella, L., Hayoz, S., Mamot, C., Rambaldi, A., Chauvie, S., & Zucca, E. (2022). Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. Hematological oncology, 40(1), 11–21. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis - Ceriani - 2022 - Hematological Oncology - Wiley Online Library

• Rekowski, J., Hüttmann, A., Schmitz, C.,  Müller, S., Kurch, L., Kotzerke, J., Franzius, C., Weckesser, M., Bengel, F., Freesmeyer, M., Hertel, A.,  Krohn T., Holzinger, J., Brink, I., Haberkorn, U., Nyuyki, F., van Assema, D., Geworski, L., Hasenclever, D.,  Jöckel K. & Dührsen, U. (2021). Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method, Journal of Nuclear Medicine, 62 (1) 37-42. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method | Journal of Nuclear Medicine

• Kurch, L., Hüttmann, A., Georgi, T. W., Rekowski, J., Sabri, O., Schmitz, C., Kluge, R., Dührsen, U., & Hasenclever, D. (2021). Interim PET in Diffuse Large B-Cell Lymphoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(8), 1068–1074. Interim PET in Diffuse Large B-Cell Lymphoma | Journal of Nuclear Medicine

• Kurch, L., Dührsen, U., Hüttmann, A., Georgi, T. W., Sabri, O., Kluge, R., & Hasenclever, D. (2021). Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma. EJNMMI research, 11(1), 90. Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma | EJNMMI Research | Full Text

• Broecker-Preuss, M., Becher-Boveleth, N., Müller, S. P., Hüttmann, A., Hanoun, C., Grafe, H., Richter, J., Klapper, W., Rekowski, J., Bockisch, A., & Dührsen, U. (2021). Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. Journal of cancer research and clinical oncology, 10.1007/s00432-021-03796-z. Advance online publication. Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial | Journal of Cancer Research and Clinical Oncology

• Zucca, E., Cascione, L., Ruberto, T., Facchinelli, D., Schär, S., Hayoz, S., Dirnhofer, S., Giovanella, L., Bargetzi, M., Mamot, C., & Ceriani, L. (2020). Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial. Hematological oncology, 38(5), 715–725. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B‐cell lymphoma: post‐hoc analysis from the SAKK38/07 clinical trial - Zucca - 2020 - Hematological Oncology - Wiley Online Library

• Luca Ceriani, Giuseppe Gritti, Luciano Cascione, Maria Cristina Pirosa, Angela Polino, Teresa Ruberto, Anastasios Stathis, Andrea Bruno, Alden A. Moccia, Luca Giovanella, Stefanie Hayoz, Sämi Schär, Stefan Dirnhofer, Alessandro Rambaldi, Giovanni Martinelli, Christoph Mamot, Emanuele Zucca; SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Adv 2020; 4 (6): 1082–1092. doi: SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model | Blood Advances | American Society of Hematology

• Wagner, B., Dührsen, U., Hüttmann, A., Nückel, H., Michita, R. T., Rohn, H., Schramm, S., Horn, P. A., & Rebmann, V. (2020). Genetic Variants of the NKG2C/HLA-E Receptor-Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma. Cancers, 12(11), 3429. Genetic Variants of the NKG2C/HLA-E Receptor–Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma

• Schmitz, C., Rekowski, J., Reinke, S., Müller, S. P., Hüttmann, A., Klapper, W., & Dührsen, U. (2020). Metabolic tumor volume, cancer cell fraction, and prognosis – the case of T-cell/histiocyte-rich large B-cell lymphoma. Leukemia & lymphoma, 61(6), 1372–1379. Full article: Metabolic tumor volume, cancer cell fraction, and prognosis – the case of T-cell/histiocyte-rich large B-cell lymphoma

• Schmitz, C., Rekowski, J., Müller, S. P., Hertenstein, B., Franzius, C., Ganser, A., Bengel, F. M., Kroschinsky, F., Kotzerke, J., La Rosée, P., Freesmeyer, M., Hoeffkes, H. G., Hertel, A., Behringer, D., Mesters, R., Weckesser, M., Mahlmann, S., Haberkorn, U., Martens, U., … Hüttmann, A. (2020). Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial. Hematological Oncology, 38(3), 244-256. Baseline and interim PET‐based outcome prediction in peripheral T‐cell lymphoma: A subgroup analysis of the PETAL trial - Schmitz - 2020 - Hematological Oncology - Wiley Online Library

• Schmitz, C., Rekowski, J., Müller, S. P., Farsijani, N., Hertenstein, B., Franzius, C., von Verschuer, U., La Rosée, P., Freesmeyer, M., Wilop, S., Krohn, T., Raghavachar, A., Ganser, A., Bengel, F. M., Prange-Krex, G., Kroschinsky, F., Kotzerke, J., Giagounidis, A., Dührsen, U., & Hüttmann, A. (2020). Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy. Cancer medicine, 9(22), 8386–8396. Impact of complete surgical resection on outcome in aggressive non‐Hodgkin lymphoma treated with immunochemotherapy - Schmitz - 2020 - Cancer Medicine - Wiley Online Library

• Schmitz, C., Hüttmann, A., Müller, S. P., Hanoun, M., Boellaard, R., Brinkmann, M., Jöckel, K. H., Dührsen, U., & Rekowski, J. (2020). Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. European journal of cancer (Oxford, England : 1990), 124, 25–36. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial - ScienceDirect

• Schmitz, C., Hüttmann, A., Müller, S. P., Hanoun, M., Boellaard, R., Brinkmann, M., Jöckel, K. H., Dührsen, U., & Rekowski, J. (2020). Corrigendum to ‘Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial’. [Eur J Canc 124 (January 2020) 25-36]. European journal of cancer (Oxford, England : 1990), 136, 207–208. Corrigendum to ‘Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial’ [Eur J Canc 124 (January 2020) 25–36] - ScienceDirect

• Schmitz, C., Hüttmann, A., Müller, S. P., Hanoun, M., Boellaard, R., Brinkmann, M., Jöckel, K. H., Dührsen, U., & Rekowski, J. (2019). Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination. Data in brief, 28, 104976. Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination - ScienceDirect

• Richter, J., Hüttmann, A., Rekowski, J., Schmitz, C., Gärtner, S., Rosenwald, A., Hansmann, M. L., Hartmann, S., Möller, P., Wacker, H. H., Feller, A., Thorns, C., Müller, S., Dührsen, U., & Klapper, W. (2019). Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome. Blood cancer journal, 9(9), 67. Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome | Blood Cancer Journal

• Hüttmann, A., Rekowski, J., Müller, S. P., Hertenstein, B., Franzius, C., Mesters, R., Weckesser, M., Kroschinsky, F., Kotzerke, J., Ganser, A., Bengel, F. M., La Rosée, P., Freesmeyer, M., Höffkes, H. G., Hertel, A., Behringer, D., Prange-Krex, G., Griesshammer, M., Holzinger, J., Wilop, S., … Dührsen, U. (2019). Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial.Annals of hematology, 98(4), 897–907. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial | Annals of Hematology

• Dührsen, U., Müller, S., Hertenstein, B., Thomssen, H., Kotzerke, J., Mesters, R., Berdel, W. E., Franzius, C., Kroschinsky, F., Weckesser, M., Kofahl-Krause, D., Bengel, F. M., Dürig, J., Matschke, J., Schmitz, C., Pöppel, T., Ose, C., Brinkmann, M., La Rosée, P., Freesmeyer, M., … PETAL Trial Investigators (2018). Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36(20), 2024–2034. Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial | Journal of Clinical Oncology

• Mamot, C., Klingbiel, D., Hitz, F., Renner, C., Pabst, T., Driessen, C., Mey, U., Pless, M., Bargetzi, M., Krasniqi, F., Gigli, F., Hany, T., Samarin, A., Biaggi, C., Rusterholz, C., Dirnhofer, S., Zucca, E., & Martinelli, G. (2015). Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(23), 2523–2529. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07) | Journal of Clinical Oncology

• Hüttmann, A., Müller, S., Jöckel, K. H., & Dührsen, U. (2010). Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(27), e488–e491. Pitfalls of Interim Positron Emission Tomography Scanning in Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology

• Dührsen, U., Hüttmann, A., Jöckel, K. H., & Müller, S. (2009). Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas–the PETAL trial. Leukemia & lymphoma, 50(11), 1757–1760. Full article: Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas – the PETAL trial

Theses

• Ferrández Ferrández M.C. (2026). Artificial Intelligence For 18-F-FDG PET/CT Prognosis in Diffuse Large B-Cell Lymphoma. [PhD-Thesis – Research and graduation internal, Vrije Universiteit Amsterdam].

• Zwezerijnen G.J.C. (2026). Quantitative Approaches for 18F-FDG PET Imaging in Lymphoma. [PhD-Thesis – Research and graduation internal, Vrije Universiteit Amsterdam].

• Eertink, J. J. (2023). New perspectives on the role of PET imaging in diffuse large B-cell lymphoma. [PhD-Thesis – Research and graduation internal, Vrije Universiteit Amsterdam].

• Burggraaff, C. N. (2022). 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation. [PhD-Thesis – Research and graduation internal, Vrije Universiteit Amsterdam].